Skip to main content

Table 3 Cox proportional hazards model analysis of death

From: Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

 

Univariable analysis

Multivariable analysis

Variable

HR

95% CI

p-value

HR

95% CI

p-value

Initial Stage

 Recurrence Vs. Metastasis

1.59

0.89 to 2.83

.119

   

M stage

 M1a Vs. M1b

1.04

0.41 to 2.66

.927

   

 M1a Vs. M1c

2.37

1.14 to 4.91

.021

   

Chemotherapy regimen

 PP

0.79

0.46 to 1.35

.380

   

 GP

0.80

0.46 to 1.40

.436

   

 TP

1.86

0.72 to 4.77

.199

   

 Pemetrexed

1.65

0.97 to 2.82

.068

1.69

0.98 to 2.91

.061

 Gemcitabine

1.12

0.55 to 2.30

.756

   

 Taxane

0.98

0.49 to 1.94

.943

   

 Navelbine

0.93

0.49 to 1.78

.833

   

 Other regimens

0.72

0.28 to 1.81

.478

   

Targeted Therapy

0.61

0.27 to 1.34

.217

  

.

 EGFR TKI

0.93

0.37 to 2.34

.878

   

 ALK TKI

0.39

0.10 to 1.63

.198

   

Immunotherapy

0.28

0.11 to 0.69

.006

0.28

0.11 to 0.71

.008

 Nivolunab

0.34

0.11 to 1.10

.072

   

 Other immunotherapy

0.04

0.00 to 4.66

.189

   
  1. HR hazard ratio, CI confidence interval, PP platinum & pemetrexed, GP gemcitabine & platinum, TP taxane & platinum
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us